New York Medical Malpractice Funding

New York medical malpractice claims must be commenced within two years and six months of the act, omission, or failure complained of under CPLR 214-a. Where there has been continuous treatment for the same condition by the same provider, the period runs from the end of that treatment. New York does not apply a general discovery rule; the exceptions are a retained foreign object, which allows one year from discovery, and Lavern's Law (2018), which for a failure to diagnose cancer or a malignant tumor allows two years and six months from the date the plaintiff knew or reasonably should have known of the negligent act, subject to a seven-year outer limit from the act itself. Claims against municipal hospitals such as NYC Health + Hospitals require a notice of claim within 90 days under General Municipal Law section 50-e and carry a shorter limitations period. New York has no certificate-of-merit or presuit screening requirement, though counsel must file a certificate of merit with the complaint under CPLR 3012-a.

Pure comparative negligence under CPLR 1411. A New York med-mal plaintiff's culpable conduct reduces the recovery in proportion to that conduct but never bars it. Patient noncompliance, delay in seeking care, or failure to disclose history are argued as comparative fault and reduce damages proportionally.

New York has no cap on non-economic, economic, or punitive damages in medical malpractice. Verdicts are subject only to judicial review for whether they deviate materially from reasonable compensation under CPLR 5501(c), which appellate courts apply through remittitur. Periodic legislative proposals to cap damages or create a patient compensation fund have not been enacted. Structured judgment rules under CPLR article 50-A govern how large future-damages awards are paid, but they do not limit the amount.

New York does not award prejudgment interest on personal injury damages before the verdict. Under CPLR 5001, interest on a personal injury award runs from the date of the verdict or decision to the entry of judgment (CPLR 5002), and then post-judgment under CPLR 5003 at the nine percent statutory rate in CPLR 5004. In wrongful death actions, interest on the pecuniary award runs from the date of death under EPTL 5-4.3.

Under CPLR 503, a med-mal action is filed in the county where any party resided when the action was commenced or where a substantial part of the events occurred — ordinarily the county of the hospital or practice. Actions against NYC Health + Hospitals and other municipal medical facilities are governed by the notice-of-claim and venue provisions of General Municipal Law section 50-e and the applicable local law, and claims against State-operated hospitals proceed in the Court of Claims.

New York regulates consumer litigation funding under the Consumer Litigation Funding Act (Article 39-H), N.Y. Gen. Bus. Law §§ 899-ccc–899-mmm. Charges to the consumer litigation funding company are capped at 25% of the gross amount recovered on the claim — disclosed verbatim, in 12-pt bold, in the funding contract.

How does the absence of any damages cap affect a New York med-mal advance?

New York caps nothing in medical malpractice, so underwriting works from the full documented damages record — future care, lost earnings, and non-economic loss — constrained only by appellate remittitur review. Birth injury and catastrophic cases are evaluated on the evidence rather than against a statutory ceiling.

The value analysis is only half the picture; liability still depends on expert proof of a departure from accepted practice and causation. Structured judgment rules under CPLR article 50-A affect how a large future-damages award is paid out, which matters to repayment timing but not to the amount. Claims against municipal hospitals carry the same uncapped exposure but a shorter limitations period.

What is the continuous treatment doctrine, and why does it matter for funding?

Under CPLR 214-a the two-and-a-half-year period runs from the end of a continuous course of treatment for the same condition, not from the initial error. This often preserves claims that would otherwise be late, but it is fact-intensive, and underwriting confirms counsel's accrual analysis before advancing.

The doctrine requires ongoing treatment for the same condition by the same provider, not merely a continuing relationship. Lavern's Law provides a separate discovery-based rule only for missed cancer diagnoses, with a seven-year outer limit. A claim whose timeliness depends on either doctrine is fundable but is evaluated with the limitations issue expressly in view.

Does the lack of prejudgment interest change the funding calculus in New York?

Yes, in a limited way. Because interest under CPLR 5001 runs only from the verdict, a New York plaintiff is not compensated for the years the case takes to reach trial. That makes non-recourse funding a practical substitute for the time value the statute does not provide.

Wrongful death claims are the exception: interest on the pecuniary award runs from the date of death under EPTL 5-4.3. For injury claims, the delay cost falls entirely on the plaintiff until verdict. Underwriting prices the expected duration explicitly, and the plaintiff should weigh the funding cost against the alternative of an early, discounted settlement.